Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of “Moderate Buy” from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has earned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $48.3636.

CAPR has been the subject of several recent analyst reports. Cantor Fitzgerald set a $62.00 target price on Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Roth Mkm restated a “buy” rating and set a $38.00 target price on shares of Capricor Therapeutics in a research report on Friday, May 15th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. B. Riley Financial boosted their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Piper Sandler restated an “overweight” rating and set a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th.

Capricor Therapeutics Trading Up 1.1%

CAPR opened at $27.64 on Thursday. Capricor Therapeutics has a 12 month low of $4.30 and a 12 month high of $40.37. The stock has a 50-day moving average of $31.34 and a 200 day moving average of $26.42. The firm has a market cap of $1.60 billion, a P/E ratio of -11.91 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last announced its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, research analysts forecast that Capricor Therapeutics will post -0.75 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the sale, the director owned 7,529 shares in the company, valued at approximately $240,928. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the sale, the chief financial officer owned 8,223 shares of the company’s stock, valued at $260,669.10. The trade was a 75.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 172,529 shares of company stock valued at $5,302,440 in the last quarter. 9.20% of the stock is owned by company insiders.

Institutional Trading of Capricor Therapeutics

Large investors have recently modified their holdings of the company. Russell Investments Group Ltd. boosted its holdings in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 2,786 shares during the period. ACT Capital Management LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $43,000. KBC Group NV purchased a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $44,000. GoalVest Advisory LLC purchased a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $59,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.